Back to results
US 2023/0019590 A1Published application
Bioinformatic processes for determination of peptide binding
AssigneeIogenetics, LLC
InventorsRobert D. Bremel, Jane Homan
Life of this patent
Estimating the term…
Abstract
This invention relates to the identification of peptide binding to ligands, and in particular to identification of epitopes expressed by microorganisms and by mammalian cells. The present invention provides polypeptides comprising the epitopes, and vaccines, antibodies and diagnostic products that utilize or are developed using the epitopes.
Claims19
A synthetic polypeptide selected from the group consisting of polypeptides comprising:
- a first peptide comprising a peptidase cleavage site and a second peptide that binds to at least one MHC binding region with a predicted affinity of greater than about 106 M−1 wherein the C terminal of the second peptide is located within 3 amino acids of the scissile bond of said peptidase cleavage site;
- and
- a first peptide that binds to at least one MHC-II binding region with a predicted affinity of greater than about 106 M−1 and a second peptide that binds to at least one MHC-I binding region with a predicted affinity of greater than about 106 M−1 wherein said first and second peptides overlap or have borders within 3 to about 20 amino acids.
A process for making a vaccine comprising:
- identifying a peptide sequence selected from the group consisting of peptides comprising:
- a first peptide comprising a peptidase cleavage site and a second peptide that binds to at least one MHC binding region with a predicted affinity of greater than about 106 M−1 wherein the C terminal of the second peptide is located within 3 amino acids of the scissile bond of said peptidase cleavage site;
- and
- a second peptide that binds to at least one MHC-II binding region with a predicted affinity of greater than about 106 M−1 and a second peptide that binds to at least one MHC-I binding region with a predicted affinity of greater than about 106 M−1 wherein said first and second peptides overlap or have borders within 3 to about 20 amino acids;
- and
- preparing a vaccine comprising said peptide sequence.
3 more elements
The process for making a vaccine of claim 20 wherein said peptide sequence also comprises a B cell epitope.
Dependencies are inferred from the claim text.